Clinical Trial: Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

U.S., Jan. 31 -- ClinicalTrials.gov registry received information related to the study (NCT06800950) titled 'Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine' on Jan. 24.

Brief Summary: This is a randomized, blinded, active-controlled phase III clinical trial to evaluate the immunogenicity and safety of the Quadrivalent Influenza Virus Split Vaccine (QIV) in subjects (aged 3 years and above). Primary immunogenicity endpoints are the geometric mean titers, geometric mean fold increases, seropositive rates, and seroconversion rates of anti-influenza virus HI antibodies for all types 30 days after immunization, and primary safety endpoints are the occurrence of safety events after vaccination including the incidence of a...